MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

PHASE2RecruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Non-Hodgkin Lymphoma, B-cell
Interventions
DRUG

MEN1703

MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).

DRUG

Glofitamab

Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.

Trial Locations (36)

28027

RECRUITING

Clinica Universidad De Navarra, Madrid

28033

RECRUITING

MD Anderson Cancer Center, Madrid

30120

NOT_YET_RECRUITING

Hospital Clínico Uni versitario Virgen de la Arrixaca, Murcia

31008

RECRUITING

Clinica Universidad De Navarra, Pamplona

RECRUITING

Hospital Universitario De Navarra, Pamplona

33600

RECRUITING

CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac

34490

RECRUITING

CHU Montpellier - Hôpital Saint Eloi, Montpellier

37007

RECRUITING

Hospital Universitario De Salamanca, Salamanca

41009

RECRUITING

Hospital Universitario Virgen De La Macarena, Seville

69310

RECRUITING

Hospices Civils De Lyon - Hôpital Lyon Sud, Lyon

72037

RECRUITING

Centre Hospitalier Le Mans, Le Mans

75651

RECRUITING

APHP - Hôpital Pitié-Salpêtrière, Paris

87042

RECRUITING

CHU de Limoges - CHU Dupuytren, Limoges

Unknown

RECRUITING

CHU de Lille - Hôpital Claude Huriez, Lille

RECRUITING

Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej, Biała Podlaska

RECRUITING

IN-VIVO Bydgoszcz Sp. z o.o., Bydgoszcz

NOT_YET_RECRUITING

Klinika Hematologii I Transplantologii Uck, Gdansk

RECRUITING

Szpitale Pomorskie Sp. z o.o., Gdynia

RECRUITING

Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy, Gliwice

RECRUITING

Pratia Hematologia Sp. z o.o., Katowice

RECRUITING

Pratia MCM Kraków, Krakow

NOT_YET_RECRUITING

SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow

RECRUITING

Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn

RECRUITING

Aidport Sp. z o.o., Skórzewo

RECRUITING

Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu, Torun

RECRUITING

Lux Med Onkologia Sp. z o.o., Warsaw

RECRUITING

Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy, Warsaw

NOT_YET_RECRUITING

Hospital Universitario Puerta de Hierro Majadahonda, Madrid

NOT_YET_RECRUITING

Hospital Universitario Miguel Servet, Zaragoza

RECRUITING

Beatson West of Scotland Cancer Centre, Glasgow

NOT_YET_RECRUITING

The Royal Marsden Hospital, London

RECRUITING

The Christie NHS Foundation Trust, Manchester

RECRUITING

Plymouth Hospitals NHS Trust, Plymouth

NOT_YET_RECRUITING

The Royal Marsden Hospital, Sutton

RECRUITING

St George's Hospital, Tooting

08035

RECRUITING

Hospital Universitari Vall D Hebron, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Menarini Group

INDUSTRY

lead

Ryvu Therapeutics SA

INDUSTRY

NCT06534437 - MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | Biotech Hunter | Biotech Hunter